Loading...

European Launches And Chinese Recovery Will Expand Precision Radiotherapy Adoption

Published
16 Mar 25
Updated
02 Sep 25
AnalystConsensusTarget's Fair Value
SEK 53.79
8.0% undervalued intrinsic discount
04 Sep
SEK 49.46
Loading
1Y
-27.4%
7D
6.4%

Author's Valuation

SEK 53.8

8.0% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on02 Sep 25
Fair value Decreased 6.93%

Despite a modest improvement in consensus revenue growth forecasts, Elekta’s future P/E multiple has edged lower, contributing to a reduced consensus analyst price target from SEK57.79 to SEK55.31. What's in the News Elekta reiterated full-year sales growth guidance for 2025–2026 but expects continued near-term sales weakness in the US and lingering negative effects from prior low orders in China; FX and tariffs expected to pressure Q2 earnings, with hopes of Chinese sales recovery later in the year.

Shared on01 May 25
Fair value Decreased 14%

Shared on24 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Increased 14%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.